Clinical Trials Directory

Trials / Completed

CompletedNCT01204515

Abdominal Symptom Phenotype Study in Children

Abdominal Symptom Phenotype: Pathways to New Biomarkers

Status
Completed
Phase
Study type
Observational
Enrollment
45 (actual)
Sponsor
Baylor College of Medicine · Academic / Other
Sex
Female
Age
7 Years – 12 Years
Healthy volunteers
Accepted

Summary

Children and adults commonly suffer from recurrent abdominal (stomach) pain. One type is called irritable bowel syndrome (IBS). IBS in adults and children is one of the most common and costly health care problems in the US. Some children have pain frequently (recurrent pain) while others rarely have pain. The investigators are conducting this study to help us answer questions about the causes and treatments, and management of IBS in children. The purpose of this study is to find out if there is more than one type of IBS in children. If there is, this will be important in deciding the best treatments. The investigators also want to learn how children with IBS differ from those who do not have recurrent abdominal (stomach) pain.

Detailed description

Functional gastrointestinal (GI) disorders (FGIDs), in particular irritable bowel syndrome (IBS) in adults and children, are among the most common and costly health care problems in the US. IBS disproportionately affects adult women (10-15% in western nations) and adolescent girls. Yet, health care providers remain challenged to provide effective clinical management. The etiology of IBS is not well defined and likely multi-factorial. A Need to Define Subgroups of IBS: This study emerges from the claim that identification of patient subgroups will advance our understanding of IBS and ultimately help develop treatment approaches. Most studies have lumped together patients with IBS into 2 groups (constipation-, diarrhea-predominant) and tested whether they differ from healthy controls. We propose that a paradigm shift is in order. We should recognize that IBS likely has multiple causes and therefore, multiple expressions. We speculate that by understanding better defined patient subgroups and linking them to newer biomarkers or tests, ultimately will further the understanding of the origins and create effective treatments.

Conditions

Timeline

Start date
2010-06-01
Primary completion
2012-08-01
Completion
2012-08-01
First posted
2010-09-17
Last updated
2013-02-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01204515. Inclusion in this directory is not an endorsement.